RECEIVED CENTRAL FAX CENTER

DEC 2 7 2086


Please type a plus sign (*) holde this box>					
PTO/SB/21 (08-00) Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.					
			Application Nur		10/568,732
TRANSMITTAL			Filing Date		3May 05
FORM		First Named Inv	rentor	Vankata. R. TARUR	
(to be used for all correspondence after initial filing)			Group Art Unit		
			Examiner Name		
Total Number of Pages in This Submission			Attorney Docket	Number	USV
ENCLOSURES (check all that apply)					
Fee Transmittal Form Fee Attached Amendment / Reply After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Request Information Disclosure Statement Certified Copy of Priority Document(s) Response to Missing Parts / Incomplete Application Response to Missing Parts under 37 CFR 1.52 or 1.53		Drawing Licensin Petition Provision Provision Change Address Terminal Request	Petition to Convert to a Provisional Application Power of Attorney, Revocation Change of Correspondence Address Terminal Disclaimer Request for Refund CD, Number of CD(s)		After Allowance Communication to Group Appeal Communication to Board of Appeals and Interferences Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Othor Enclosure(s) (please identify below): Copu of 30 Oct 06
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT					
Firm Mark Pohl, F.sq., USPTO Reg. No. 35,325					
Pharmaceutical Patent Attorneys, LLC 55 Madison Avenue, 4th floor, Morristown NI 07960-7397 USA					7060 7207 170 4
Signature	55 Madison Avenue, 4th floor, Morristown, NJ. (17960-7397 USA				
Date					
OFFICIAL OF MAN WE					
CERTIFICATE OF MAILING I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date:					
Typed or printed name	·				
Signature		_		Date	27 Dac 06

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Page 1 of 3

CENTRAL FAX CENTER

DEC 27 2006





United States Palent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Addisor COMMISSIONER FOR PATENTS FO. Bes. 159 Absentia, Vaginia 22313-1420 www.hopfic.gov

U.S. APPLICATION NUMBER NO. ATTY, DOCKET NO. FIRST NAMED APPLICANT 10/568,732 Vankata R. Tarur USV

INTERNATIONAL APPLICATION NO.

22925 PHARMACEUTICAL PATENT ATTORNEYS, LLC 55 MADISON AVENUE 4TH FLOOR MORRISTOWN, NJ 07960-7397

9739846159

PCT/IN05/00139 I.A. FILING DATE PRIORITY DATE 05/03/2005 05/07/2004

CONFIRMATION NO. 4931 371 FORMALITIES LETTER *OC000000021020019*

Date Mailed: 10/30/2006

NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as a Designated / Elected Office (37 CFR 1.495).

- Copy of the International Application filed on 02/17/2006
- Copy of the International Search Report filed on 02/17/2006
- Copy of Article 19 Amendments filed on 02/17/2006
- Oath or Declaration filed on 02/17/2006
- Request for Immediate Examination filed on 02/17/2006
- U.S. Basic National Fees filed on 02/17/2006
- Priority Documents filed on 02/17/2006
- Specification filed on 02/17/2006
- Claims filed on 02/17/2006
- Abstracts filed on 02/17/2006

The applicant needs to satisfy supplemental fees problems indicated below.

The following items MUST be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

- Additional claim fees of \$1360 as a non-small critity, including any required multiple dependent claim fee, are required. Applicant must submit the additional claim fees or cancel the additional claims for which fees are due.
- ✓ Oath or declaration of the inventors, in compliance with 37 CFR 1.497(a) and (b), identifying the application by the International application number and international filing date. The current oath or declaration does not comply with 37 CFR 1.497(a) and (b) in that it:
 - is not executed in accordance with either 37 CFR 1.66 or 37 CFR 1.68.
 - not executed by Inventor Swapnil Jayant Kulkami

PAGE 2/12 * RCVD AT 12/27/2006 6:07:08 PM [Eastern Standard Time] * SVR:USPTO-EFXRF-5/6 * DNIS:2738300 * CSID:9739846159 * DURATION (mm-ss):03-34

Page 2 of 3

RECEIVED CENTRAL FAX CENTER

SUMMARY OF FEES DUE:

DEC 2 7 2006

Total additional fees required for this application is \$1360 for a Large Entity:

- This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c) Applicant must provide an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment specifically directing its entry into the application and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.
- Total additional claim fee(s) for this application is \$ 1360
 - \$200 for 1 independent claims over 3.
 - \$800 for 16 total claims over 20. 3 6
 - \$360 for multiple dependent claim surchare.

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov

ALL OF THE ITEMS SET FORTH ABOVE MUST BE SUBMITTED WITHIN TWO (2) MONTHS FROM THE DATE OF THIS NOTICE OR BY 32 MONTHS FROM THE PRIORITY DATE FOR THE APPLICATION, WHICHEVER IS LATER. FAILURE TO PROPERLY RESPOND WILL RESULT IN ABANDONMENT.

The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR 1.136(a).

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

Registered users of EFS-Web may alternatively submit their reply to this notice via EFS-Web. https://sportal.uspto.gov/authenticate/Authenticate/Authenticate/EPF.html

For more information about EFS-Web please call the USPTO Electronic Business Center at 1-866-217-9197 or visit our website at http://www.uspto.gov/ebc.

PAGE 3/12 * RCVD AT 12/27/2006 6:07:08 PM [Eastern Standard Time] * SVR:USPTO-EFXRF-5/6 * DNIS:2738300 * CSID:9739846159 * DURATION (mm-ss):03-34

If you are not using EFS-Web to submit your reply, you must include a copy of this notice.

BARBARA A CAMPBELL

Telephone: (703) 308-9140 EXT 217

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO. INTERNATIONAL APPLICATION NO. ATTY. DOCKET NO. 10/568,732 PCT/IN05/00139 USV

FORM PCT/DO/EO/905 (371 Formalities Notice)